Short, occasional writing on what we're seeing in client work and in the research — not a content calendar.
Most longevity intake conversations start with diet. Ours increasingly start with sleep. Across the health systems we track, sleep duration and consistency show up as a stronger predictor of near-term biomarker changes than most dietary interventions we test for — and it's usually the easier of the two to move. We now ask about sleep before we ask about anything else, and we treat a poor sleep pattern as a reason to delay other changes rather than pile a third intervention on top of two that are already failing.
Strip away the branding, the supplement lines, and the conference keynotes, and the international literature converges on a shorter list than most marketing suggests: consistent movement, adequate protein, sleep, strong social ties, and routine screening account for most of the modifiable difference in healthy lifespan we can currently measure. Everything else — most of it interesting, some of it promising — sits on a thinner evidence base. We tell clients this directly, including when it disappoints them.
Family office clients are used to thinking in decades for capital and in quarters for everything else. Health planning tends to inherit the quarterly habit — a new test, a new number, a reaction. Part of our job is convincing clients to apply their own long-horizon instincts to their health, where a plan can look unremarkable quarter to quarter and still be exactly right.
Clients occasionally arrive having optimized one number aggressively, at the expense of everything else we'd want to look at. A single biomarker is a data point, not a diagnosis, and definitely not a strategy. Our assessments are built to resist the temptation to chase one metric — which is harder than it sounds when that metric is easy to test and easy to compare against a friend's.
See how Global Longevity Intelligence turns this thinking into a personal plan.
Read our approach